MedTrace Logo

Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

NCT00422565 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2022-12-07

No results posted yet for this study

Summary

The trial has the following primary objective:

To compare the safety and effectiveness of primary acute MI intervention with ABT 578-eluting balloon expandable stent (Medtronic, Minneapolis, MN) vs. sirolimus-eluting balloon expandable stent (Cordis Johnson \& Johnson, Warren, New Jersey) vs. paclitaxel-eluting stent (Taxus Liberte, Boston Scientific).

Conditions

Interventions

DEVICE

Endeavor, Medtronic

Zotarolimus-eluting stent

DEVICE

Cypher, Cordis

Sirolimus-eluting stent

DEVICE

Taxus Liberte, Boston Scientific

Paclitaxel-eluting stent

Sponsors & Collaborators

  • Cordis Corporation

    collaborator INDUSTRY

  • CardioVascular Research Foundation, Korea

    collaborator OTHER

  • Seung-Jung Park

    lead OTHER

Principal Investigators

  • Seung-Jung Park, MD, PhD · Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422565 on ClinicalTrials.gov